19 Feb 2026 · 2 min read
$1.7B for Takeda x Iambic last week. Now Merck skips techbio entirely and goes to Mayo Clinic.
Two pharma-AI deals in two weeks, two completely different architectures. Takeda paid $1.7B for Iambic. Now Merck skips techbio entirely and runs its AI models inside Mayo Clinic’s secure data environment. The architecture behind the Merck deal is what matters.